These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38357092)

  • 1. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From
    Zhang B; Lewis W; Stewart CA; Morris BB; Solis LM; Serrano A; Xi Y; Wang Q; Lopez ER; Concannon K; Heeke S; Tang X; Raso G; Cardnell RJ; Vokes N; Blumenschein G; Elamin Y; Fosella F; Tsao A; Skoulidis F; Hume CB; Sasak K; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Tran H; Zhang J; Gibbons D; Vaporciyan A; Wang J; Park K; Heymach JV; Byers LA; Gay CM; Le X
    JTO Clin Res Rep; 2024 Feb; 5(2):100623. PubMed ID: 38357092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment.
    Chen Y; He M; Dai Z; Wang Y; Chen J; Wang X; Dong X; Huang J; Ruan J; Zhang X; Shen P; Jia Y
    Front Oncol; 2023; 13():1308313. PubMed ID: 38188289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of
    Zhang SL; Zhang CY; Chen YQ; Li YF; Xie Z; Zhang XC; Zhou Q; Zhong WZ; Huang J; Sun H; Zheng MY; Xiao FM; Yan HH; Lu DX; Lv ZY; Wu YL; Chen HJ; Yang JJ
    J Thorac Dis; 2023 Sep; 15(9):4620-4635. PubMed ID: 37868836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
    Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
    Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.
    Ferrer L; Giaj Levra M; Brevet M; Antoine M; Mazieres J; Rossi G; Chiari R; Westeel V; Poudenx M; Letreut J; Gervais R; Osman G; Girard N; Toffart AC; Novello S; Moro-Sibilot D
    J Thorac Oncol; 2019 Jan; 14(1):130-134. PubMed ID: 30217489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis.
    Xu J; Xu L; Wang B; Kong W; Chen Y; Yu Z
    Front Oncol; 2021; 11():766148. PubMed ID: 35223450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and molecular characteristics of
    Yu L; Bazhenova L; Gold K; Tran L; Hilburn V; Vu P; Patel SP
    Transl Lung Cancer Res; 2022 Mar; 11(3):452-461. PubMed ID: 35399568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of genetic sequencing in patients with lung adenocarcinoma with transformation to small cell lung cancer: a case report and systematic review.
    Zhang C; Lin L; Guo X; Chen P
    Transl Cancer Res; 2020 May; 9(5):3725-3733. PubMed ID: 35117735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
    Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
    Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
    Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
    Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
    Mambetsariev I; Arvanitis L; Fricke J; Pharaon R; Baroz AR; Afkhami M; Koczywas M; Massarelli E; Salgia R
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
    Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
    Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment.
    Vendrell JA; Quantin X; Serre I; Solassol J
    Ther Adv Med Oncol; 2020; 12():1758835920974192. PubMed ID: 33414847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.